HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cannabis use disorder — Clinical Guidelines

Overview

Cannabis use disorder (CUD) involves problematic patterns of cannabis use leading to clinically significant impairment or distress 3. It encompasses a range of psychological and physical adverse effects, particularly concerning in pediatric and adolescent populations 1 6.

Diagnosis

Key Diagnostic Criteria: DSM-5 criteria for substance use disorders, including impaired control over use, social impairment, risky use, and pharmacological criteria 3.

Recommended Tests: No specific laboratory tests; diagnosis primarily clinical with consideration of self-report questionnaires and behavioral assessments 3.

Grading: Severity graded based on the number of diagnostic criteria met 3.

Management

First-Line Treatments: Cognitive Behavioral Therapy (CBT) and motivational interviewing 3.

Pharmacotherapies:

- Varenicline: Shown to reduce cannabis use (specific doses not detailed) 3. - Bupropion: Emerging evidence suggests potential efficacy, though specific dosing not specified 3. - Gabapentin: Some evidence of benefit, but further research needed 3.

Adjunctive Treatments: Concomitant psychotherapy often recommended alongside pharmacotherapy 3.

Special Populations

Pediatrics: Growing concern over rising emergency department visits related to cannabis use, highlighting the need for careful monitoring and education 6.

Adolescents: Casual use poses significant risks similar to those with diagnosed CUD, emphasizing prevention and early intervention 2.

Comorbidities: Potential for significant drug interactions, particularly with CYP450 substrates, necessitating careful medication management 4.

Key Recommendations

Prioritize Psychosocial Interventions: Cognitive Behavioral Therapy and motivational interviewing should be first-line treatments for CUD (Evidence: Strong 3).

Consider Pharmacotherapy for Severe Cases: Use of pharmacotherapies like varenicline, bupropion, and gabapentin should be considered for patients with severe CUD, though evidence varies (Evidence: Moderate 3).

Monitor Pediatric and Adolescent Use Closely: Given the rising incidence of cannabis-related emergencies in younger populations, heightened vigilance and targeted prevention programs are essential (Evidence: Moderate 6).

Be Cautious with Polypharmacy: Due to potential significant drug interactions, especially with CYP450 substrates, careful monitoring is required in patients using multiple medications (Evidence: Moderate 4).

References

1 Chapin MR, Kane-Gill SL, Li X, Abanyie K, Taneja SB, Egbert S et al.. Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports. Pharmacology research & perspectives 2025. link 2 . Casual Pot Use Is Harmful to Teens. The American journal of nursing 2023. link 3 Bahji A, Meyyappan AC, Hawken ER, Tibbo PG. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. The International journal on drug policy 2021. link 4 Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. The AAPS journal 2021. link 5 Crescioli G, Lombardi N, Bettiol A, Menniti-Ippolito F, Da Cas R, Parrilli M et al.. Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. British journal of clinical pharmacology 2020. link 6 Chen YC, Klig JE. Cannabis-related emergencies in children and teens. Current opinion in pediatrics 2019. link 7 Hädener M, Gelmi TJ, Martin-Fabritius M, Weinmann W, Pfäffli M. Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute". International journal of legal medicine 2019. link 8 López Pelayo H, Miquel De Montagut L, Casajuana Kögel C, Balcells Oliveró M. Post-truth Cannabis use: back to evidence-based medicine. Adicciones 2018. link 9 Uhl M, Sachs H. Cannabinoids in hair: strategy to prove marijuana/hashish consumption. Forensic science international 2004. link 10 Thomas H. A community survey of adverse effects of cannabis use. Drug and alcohol dependence 1996. link01277-x) 11 Solomons K, Neppe VM. Cannabis--its clinical effects. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1989. link 12 . Cannabis, 1977. Annals of internal medicine 1978. link

Cannabis use disorder